Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × bavituximab × Clear all

NCT02685306 2017-03-09

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms